The homologous recombination repair (HRR) pathway repairs double-strand DNA breaks, mostly by BRCA1 and BRCA2, although other proteins such as ATM, CHEK2, and PALB2 are also involved. germline mutations are targeted by PARP inhibitors. The aim of this commentary is to explore whether germline mutations in HRR-related genes other than have to be considered as prognostic factors or predictive to therapies by discussing the results of two articles published in December 2020. The TBCRC 048 trial published by Tung et al. showed an impressive objective response rate to olaparib in metastatic breast cancer patients with germline mutation compared to germline and mutation carriers. Additionally, Yadav et al. observed a significantly longer overall survival in pancreatic adenocarcinoma patients with germline HRR mutations compared to non-carriers. In our opinion, assuming that is a high-penetrant gene with a key role in the HRR system, mutations are predictive factors for response to treatment. Moreover, germline mutations in the gene provide a better outcome in pancreatic adenocarcinoma, being more often associated to wild-type . In conclusion, sequencing of HRR-related genes other than should be routinely offered as part of a biological characterization of pancreatic and breast cancers.